Beyond PSMA, Other antigen targets

[Javelin18]

Dr Dorff gave a presentation on prostate cancer (PCa) therapeutic antigen targets at the ASCO GU conference last weekend. Much of the new work in PCa treatment focuses on attaching a therapeutic payload to a molecule that binds to a prostate cancer antigen. Lu-PSMA is an example of this therapy. Currently there are other trials that use PSMA and other antigens to target PCa cells.

Her talk discusses some other antigens that are being targeted. I thought I would pass this on as basic background information.

urotoday.com/conference-hig...

[hansjd]

Thanks a lot for this post. Important information!

[MateoBeach]

Thank you for posting it.

[Javelin18]

This post turned out to be prescient. Dr Dorff and I were planning for me to be in the second cohort that would receive two infusions. The start of that dose escalation phase is a bit delayed. I need to discuss whether it is better to wait for that, or join a different trial that targets a different antigen.